Unipharma Co., Ltd.(TW:6621)
NT$12.00-0.15 (-1.23%)
TW:6621
Unipharma Co., Ltd. financials statements
NT$12.00
At close:-0.15 (-1.23%)
Unipharma Co., Ltd. (6621) Ratios
Unipharma Co., Ltd. Ratios
TW:6621's free cash flow for Q2 2026 was NT$-25.80M. For the 2026 fiscal year, TW:6621's free cash flow was decreased by NT$-508.00K and operating cash flow was NT$-25.30M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.86 | 6.03 | 6.10 | 8.28 | 5.59 |
| Quick Ratio | 4.04 | 5.36 | 5.32 | 7.20 | 4.82 |
| Cash Ratio | 0.76 | 1.77 | 1.85 | 2.22 | 1.62 |
| Solvency Ratio | -0.74 | -0.40 | -0.43 | -0.03 | -1.26 |
| Operating Cash Flow Ratio | -0.97 | -0.43 | 0.32 | -1.10 | -0.28 |
| Short-Term Operating Cash Flow Coverage | -9.88 | -2863.40 | 2406.80 | 53.29 | 0.00 |
| Net Current Asset Value | NT$ 139.27M | NT$ 155.79M | NT$ 188.83M | NT$ 208.95M | NT$ 210.78M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.04 | 0.00 | 0.01 | 0.02 |
| Debt-to-Equity Ratio | 0.05 | 0.05 | 0.00 | 0.01 | 0.02 |
| Debt-to-Capital Ratio | 0.05 | 0.05 | 0.00 | 0.01 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.20 | 1.16 | 1.12 | 1.10 | 1.17 |
| Debt Service Coverage Ratio | -9.74 | -156.77 | -855.47 | 2.62 | -641.63 |
| Interest Coverage Ratio | -445.71 | -285.38 | -1950.36 | -535.28 | -406.27 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | -0.00 | 0.00 |
| Interest Debt Per Share | 0.31 | 0.42 | 0.01 | 0.10 | 0.20 |
| Net Debt to EBITDA | 0.49 | 2.48 | 4.21 | 41.42 | 1.09 |
| Profitability Margins | |||||
| Gross Profit Margin | 46.52% | 52.12% | 49.42% | 58.25% | 56.29% |
| EBIT Margin | -49.89% | -26.44% | -21.12% | -5.45% | -70.51% |
| EBITDA Margin | -41.98% | -18.96% | -15.75% | -1.13% | -60.27% |
| Operating Profit Margin | -49.89% | -32.98% | -26.45% | -16.30% | -38.17% |
| Pretax Profit Margin | -45.84% | -26.56% | -21.13% | -5.49% | -70.60% |
| Net Profit Margin | -45.84% | -26.56% | -21.13% | -5.03% | -70.60% |
| Continuous Operations Profit Margin | -45.84% | -26.56% | -21.13% | -5.49% | -70.60% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 91.73% | 100.00% |
| EBT Per EBIT | 91.88% | 80.53% | 79.89% | 33.66% | 184.99% |
| Return on Assets (ROA) | -14.74% | -7.54% | -6.23% | -1.94% | -21.37% |
| Return on Equity (ROE) | -17.64% | -8.72% | -6.98% | -2.13% | -25.00% |
| Return on Capital Employed (ROCE) | -18.61% | -10.42% | -8.72% | -6.87% | -13.35% |
| Return on Invested Capital (ROIC) | -18.33% | -10.29% | -8.72% | -6.81% | -13.19% |
| Return on Tangible Assets | -14.94% | -7.63% | -6.27% | -1.95% | -21.53% |
| Earnings Yield | -9.55% | -5.05% | -4.15% | -1.17% | -18.30% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.89 | 5.54 | 4.86 | 3.76 | 4.59 |
| Payables Turnover | 2.62 | 3.09 | 2.35 | 8.78 | 1.67 |
| Inventory Turnover | 1.51 | 2.01 | 1.80 | 1.72 | 1.28 |
| Fixed Asset Turnover | 4.77 | 3.93 | 8.92 | 14.67 | 7.83 |
| Asset Turnover | 0.32 | 0.28 | 0.29 | 0.39 | 0.30 |
| Working Capital Turnover Ratio | 0.56 | 0.53 | 0.52 | 0.60 | 0.49 |
| Cash Conversion Cycle | 164.28 | 129.37 | 121.95 | 267.45 | 145.21 |
| Days of Sales Outstanding | 61.93 | 65.83 | 75.12 | 97.17 | 79.58 |
| Days of Inventory Outstanding | 241.54 | 181.66 | 202.36 | 211.86 | 284.79 |
| Days of Payables Outstanding | 139.18 | 118.13 | 155.54 | 41.59 | 219.16 |
| Operating Cycle | 303.47 | 247.50 | 277.49 | 309.03 | 364.37 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.03 | -0.40 | 0.34 | -0.89 | -0.37 |
| Free Cash Flow Per Share | -1.07 | -0.48 | 0.11 | -0.90 | -0.46 |
| Dividend Paid and CapEx Coverage Ratio | -28.11 | -5.04 | 1.48 | -72.76 | -4.03 |
| Capital Expenditure Coverage Ratio | -28.11 | -5.04 | 1.48 | -72.76 | -4.03 |
| Operating Cash Flow Coverage Ratio | -3.34 | -0.97 | 43.44 | -8.97 | -1.85 |
| Operating Cash Flow to Sales Ratio | -0.41 | -0.15 | 0.12 | -0.25 | -0.12 |
| Free Cash Flow Yield | -8.95% | -3.49% | 0.75% | -5.82% | -3.97% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.49 | -19.79 | -24.26 | -86.39 | -5.47 |
| Price-to-Sales (P/S) Ratio | 4.80 | 5.26 | 5.09 | 4.31 | 3.86 |
| Price-to-Book (P/B) Ratio | 1.85 | 1.73 | 1.68 | 1.82 | 1.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.18 | -28.66 | 133.90 | -17.20 | -25.19 |
| Price-to-Operating Cash Flow Ratio | -11.57 | -34.34 | 43.66 | -17.43 | -31.44 |
| Price-to-Earnings Growth (PEG) Ratio | -0.17 | -1.34 | -0.10 | 0.94 | -0.16 |
| Enterprise Value Multiple | -10.95 | -25.28 | -28.12 | -338.08 | -5.31 |
| Enterprise Value | 406.57M | 447.80M | 457.05M | 491.56M | 337.61M |
| EV to EBITDA | -10.95 | -25.28 | -28.12 | -338.08 | -5.31 |
| EV to Sales | 4.60 | 4.79 | 4.43 | 3.84 | 3.20 |
| EV to Free Cash Flow | -10.70 | -26.10 | 116.47 | -15.32 | -20.92 |
| EV to Operating Cash Flow | -11.08 | -31.28 | 37.98 | -15.53 | -26.10 |
| Tangible Book Value Per Share | 6.37 | 7.92 | 8.75 | 8.48 | 8.38 |
| Shareholders’ Equity Per Share | 6.47 | 8.02 | 8.81 | 8.55 | 8.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 2.49 | 2.63 | 2.91 | 3.61 | 2.99 |
| Net Income Per Share | -1.14 | -0.70 | -0.61 | -0.18 | -2.11 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.92 | 1.00 |
| Interest Burden | 0.92 | 1.00 | 1.00 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.23 | 0.18 | 0.17 | 0.21 | 0.31 |
| SG&A to Revenue | 0.73 | 0.67 | 0.59 | 0.54 | 0.63 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.90 | 0.58 | -0.55 | 3.53 | 0.17 |
Currency in TWD
